<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38932408</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Assessing Predictive Value of SARS-CoV-2 Epitope-Specific CD8<sup>+</sup> T-Cell Response in Patients with Severe Symptoms.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">679</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12060679</ELocationID><Abstract><AbstractText>Specific T cell responses against SARS-CoV-2 provided an overview of acquired immunity during the pandemic. Anti-SARS-CoV-2 immunity determines the severity of acute illness, but also might be related to the possible persistence of symptoms (long COVID). We retrospectively analyzed ex vivo longitudinal CD8<sup>+</sup> T cell responses in 26 COVID-19 patients diagnosed with severe disease, initially (1 month) and long-term (10 months), and in a cohort of 32 vaccinated healthcare workers without previous SARS-CoV-2 infection. We used peptide-human leukocyte antigen (pHLA) dextramers recognizing 26 SARS-CoV-2-derived epitopes of viral and other non-structural proteins. Most patients responded to at least one of the peptides studied, mainly derived from non-structural ORF1ab proteins. After 10 months follow-up, CD8<sup>+</sup> T cell responses were maintained at long term and reaction against certain epitopes (A*01:01-ORF1ab1637) was still detected and functional, showing a memory-like phenotype (CD127+ PD-1+). The total number of SARS-CoV-2-specific CD8<sup>+</sup> T cells was significantly associated with protection against long COVID in these patients. Compared with vaccination, infected patients showed a less effective immune response to spike protein-derived peptides restricted by HLA. So, the A*01:01-S865 and A*24:02-S1208 dextramers were only recognized in vaccinated individuals. We conclude that initial SARS-CoV-2-specific CD8<sup>+</sup> T cell response could be used as a marker to understand the evolution of severe disease and post-acute sequelae after SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;n-Mart&#xed;n</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Riego</LastName><ForeName>Estefan&#xed;a Salgado</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0003-4834-9263</Identifier><AffiliationInfo><Affiliation>Service of Intensive Medicine, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casti&#xf1;eira</LastName><ForeName>Jose R Vidal</ForeName><Initials>JRV</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zapico-Gonzalez</LastName><ForeName>Maria Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-P&#xe9;rez</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Microbiology, Health Research Institute of Principado de Asturias (ISPA), 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corte-Iglesias</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saiz</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Bulnes</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudero</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service of Intensive Medicine, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Microbiology, Health Research Institute of Principado de Asturias (ISPA), 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Alvarez</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Larrea</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI19/00184, PI20/00639 and PI22/00738</GrantID><Agency>Instituto de Salud Carlos III (ISCIII) through projects co-funded by the European Union</Agency><Country/></Grant><Grant><GrantID>IFEQ21/00203</GrantID><Agency>European Union through Next Generation EU funds, which support the actions of the Mecanismo de Recuperaci&#xf3;n y Resiliencia (MRR).</Agency><Country/></Grant><Grant><GrantID>Grant IDI/2021/000032</GrantID><Agency>PCTI-Plan de Ciencia, Tecnolog&#xed;a e Innovaci&#xf3;n 2021-2023 from the Gobierno del Principado de Asturias</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">epitope-specific CD8+ T cell</Keyword><Keyword MajorTopicYN="N">humoral response</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">pHLA dextramers</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932408</ArticleId><ArticleId IdType="pmc">PMC11209605</ArticleId><ArticleId IdType="doi">10.3390/vaccines12060679</ArticleId><ArticleId IdType="pii">vaccines12060679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet. 2020;395:507&#x2013;513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Vig&#xf3;n L., Fuertes D., Garc&#xed;a-P&#xe9;rez J., Torres M., Rodr&#xed;guez-Mora S., Mateos E., Corona M., Saez-Mar&#xed;n A.J., Malo R., Navarro C., et al. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Front. Immunol. 2021;12:665329. doi: 10.3389/fimmu.2021.665329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.665329</ArticleId><ArticleId IdType="pmc">PMC8187764</ArticleId><ArticleId IdType="pubmed">34122423</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Larson C., Hammond T.C., Oronsky A., Kesari S., Lybeck MReid T.R. A Review of Persistent Post-COVID Syndrome (PPCS) Clin. Rev. Allergy Immunol. 2021;64:66&#x2013;74. doi: 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical Predictors of Mortality Due to COVID-19 Based on an Analysis of Data of 150 Patients From Wuhan, China. Intensive Care Med. 2020;46:846&#x2013;848. doi: 10.1007/s00134-020-05991-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan N.A. A Negative COVID-19 Test Does Not Mean Recovery. Nature. 2020;584:170. doi: 10.1038/d41586-020-02335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02335-z</ArticleId><ArticleId IdType="pubmed">32782377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183:996&#x2013;1012.e19. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbaz S., Xu L., Sligl W., Osman M., Bozorgmehr N., Mashhouri S., Redmond D., Rosero E.P., Walker J., Elahi S. The Quality of SARS-CoV-2-Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated. J. Immunol. 2021;207:1099&#x2013;1111. doi: 10.4049/jimmunol.2100446.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100446</ArticleId><ArticleId IdType="pubmed">34312258</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489&#x2013;1501.e15. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457&#x2013;462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Str&#xe5;lin K., Gorin J.-B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158&#x2013;168.e14. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sureshchandra S., Lewis S.A., Doratt B.M., Jankeel A., Coimbra Ibraim I., Messaoudi I. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. JCI Insight. 2021;6:e153201. doi: 10.1172/jci.insight.153201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.153201</ArticleId><ArticleId IdType="pmc">PMC8783687</ArticleId><ArticleId IdType="pubmed">34935643</ArticleId></ArticleIdList></Reference><Reference><Citation>Salgado Del Riego E., Saiz M.L., Corte-Iglesias V., Gordillo B.L., Martin-Martin C., Rodr&#xed;guez-P&#xe9;rez M., Escudero D., Lopez-Larrea C., Suarez-Alvarez B. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination. Front. Immunol. 2022;13:942192. doi: 10.3389/fimmu.2022.942192.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.942192</ArticleId><ArticleId IdType="pmc">PMC9582956</ArticleId><ArticleId IdType="pubmed">36275696</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.X., Liu B.Z., Deng H.J., Wu G.C., Deng K., Chen Y.K., Liao P., Qiu J.F., Lin Y., Cai X.F., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020;26:845&#x2013;848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurtz V., Paul S., Andreatta M., Marcatili P., Peters B., Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. J. Immunol. 2017;199:3360&#x2013;3368. doi: 10.4049/jimmunol.1700893.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700893</ArticleId><ArticleId IdType="pmc">PMC5679736</ArticleId><ArticleId IdType="pubmed">28978689</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C.Y., Xu J., He J.Q., Lu Y.Q. Immune dysfunction following COVID-19, especially in severe patients. Sci. Rep. 2020;10:15838. doi: 10.1038/s41598-020-72718-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72718-9</ArticleId><ArticleId IdType="pmc">PMC7522270</ArticleId><ArticleId IdType="pubmed">32985562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha M.S., Shin E.C. Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cell Mol. Immunol. 2021;18:2325&#x2013;2333. doi: 10.1038/s41423-021-00750-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00750-4</ArticleId><ArticleId IdType="pmc">PMC8374113</ArticleId><ArticleId IdType="pubmed">34413488</ArticleId></ArticleIdList></Reference><Reference><Citation>Heim K., Neumann-Haefelin C., Thimme R., Hofmann M. Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. Front. Immunol. 2019;10:2240. doi: 10.3389/fimmu.2019.02240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02240</ArticleId><ArticleId IdType="pmc">PMC6763562</ArticleId><ArticleId IdType="pubmed">31620140</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney E.F., Lee J.C., Jayne D.R., Lyons P.A., Smith K.G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523:612&#x2013;616. doi: 10.1038/nature14468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14468</ArticleId><ArticleId IdType="pmc">PMC4623162</ArticleId><ArticleId IdType="pubmed">26123020</ArticleId></ArticleIdList></Reference><Reference><Citation>Radziewicz H., Ibegbu C.C., Fernandez M.L., Workowski K.A., Obideen K., Wehbi M., Hanson H.L., Steinberg J.P., Masopust D., Wherry E.J., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 2007;81:2545&#x2013;2553. doi: 10.1128/JVI.02021-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02021-06</ArticleId><ArticleId IdType="pmc">PMC1865979</ArticleId><ArticleId IdType="pubmed">17182670</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Ellingson M.K., Wong P., Israelow B., Lucas C., Klein J., Silva J., Mao T., Oh J.E., Tokuyama M., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315&#x2013;320. doi: 10.1038/s41586-020-2700-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T., Ryu H., McGregor M., Babcock B., Neidleman J., Xie G., George A.F., Frouard J., Murray V., Gill G., et al. Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells during Convalescence. J. Immunol. 2021;207:1344&#x2013;1356. doi: 10.4049/jimmunol.2100465.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100465</ArticleId><ArticleId IdType="pmc">PMC8763019</ArticleId><ArticleId IdType="pubmed">34389625</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J., Luo X., Frouard J., Xie G., Gill G., Stein E.S., McGregor M., Ma T., George A.F., Kosters A., et al. SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep. Med. 2020;1:100081. doi: 10.1016/j.xcrm.2020.100081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100081</ArticleId><ArticleId IdType="pmc">PMC7437502</ArticleId><ArticleId IdType="pubmed">32839763</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J., Luo X., George A.F., McGregor M., Yang J., Yun C., Murray V., Gill G., Greene W.C., Vasquez J., et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021;36:109414. doi: 10.1016/j.celrep.2021.109414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109414</ArticleId><ArticleId IdType="pmc">PMC8238659</ArticleId><ArticleId IdType="pubmed">34260965</ArticleId></ArticleIdList></Reference><Reference><Citation>Santopaolo M., Gregorova M., Hamilton F., Arnold D., Long A., Lacey A., Oliver E., Halliday A., Baum H., Hamilton K., et al. Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months. eLife. 2023;12:e85009. doi: 10.7554/eLife.85009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.85009</ArticleId><ArticleId IdType="pmc">PMC10319436</ArticleId><ArticleId IdType="pubmed">37310006</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz T., Mendoza N., Lled&#xf3; G.M., Perea L., Albacar N., Agust&#xed; A., Sellares J., Sibila O., Faner R. Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19. ERJ Open Res. 2023;9:00020-2023. doi: 10.1183/23120541.00020-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00020-2023</ArticleId><ArticleId IdType="pmc">PMC10204814</ArticleId><ArticleId IdType="pubmed">37228290</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Zaunders J., Kelleher A. Detecting antigen-specific T cell responses: From bulk populations to single cells. Int. J. Mol. Sci. 2015;16:18878&#x2013;18893. doi: 10.3390/ijms160818878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160818878</ArticleId><ArticleId IdType="pmc">PMC4581277</ArticleId><ArticleId IdType="pubmed">26274954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji N., Forsthuber T.G. ELISPOT techniques. Methods Mol. Biol. 2016;1304:63&#x2013;71. doi: 10.1007/7651_2014_111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/7651_2014_111</ArticleId><ArticleId IdType="pubmed">25117217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangaev A., Ketelaars S.L.C., Isaeva O.I., Patiwael S., Dopler A., Hoefakker K., De Biasi S., Gibellini L., Mussini C., Guaraldi G., et al. Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. Nat. Commun. 2021;12:2593. doi: 10.1038/s41467-021-22811-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22811-y</ArticleId><ArticleId IdType="pmc">PMC8110804</ArticleId><ArticleId IdType="pubmed">33972535</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini S.K., Hersby D.S., Tamhane T., Povlsen H.R., Hernandez S.P.A., Nielsen M., Gang A.O., Hadrup S.R. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 + T cell activation in COVID-19 patients. Sci. Immunol. 2021;6:eabf7550. doi: 10.1126/sciimmunol.abf7550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf7550</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowntree L.C., Nguyen T.H.O., Kedzierski L., Neeland M.R., Petersen J., Crawford J.C., Allen L.F., Clemens E.B., Chua B., McQuilten H.A., et al. SARS-CoV-2-specific T cell memory with common TCR&#x3b1;&#x3b2; motifs is established in unvaccinated children who seroconvert after infection. Immunity. 2022;55:1299&#x2013;1315.e4. doi: 10.1016/j.immuni.2022.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.06.003</ArticleId><ArticleId IdType="pmc">PMC9174177</ArticleId><ArticleId IdType="pubmed">35750048</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Wang J., Sun P., Qin J., Yang X., Chen D., Zhang Y., Zhong N., Wang Z. SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. Front. Immunol. 2023;14:1146196. doi: 10.3389/fimmu.2023.1146196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1146196</ArticleId><ArticleId IdType="pmc">PMC10036809</ArticleId><ArticleId IdType="pubmed">36969254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann C., Mayer C.K., Claassen M., Maponga T., Burgers W.A., Keeton R., Riou C., Sutherland A.D., Suliman T., Shaw M.L., et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399:625&#x2013;626. doi: 10.1016/S0140-6736(22)00090-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00090-3</ArticleId><ArticleId IdType="pmc">PMC8765759</ArticleId><ArticleId IdType="pubmed">35063123</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha M.-S., Jeong H.W., Ko J.-H., Choi S.J., Seo I.-H., Lee J.S., Sa M., Kim A.R., Joo E.-J., Ahn J.Y., et al. PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19. Immunity. 2021;54:44&#x2013;52.e3. doi: 10.1016/j.immuni.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7834198</ArticleId><ArticleId IdType="pubmed">33338412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Pouwels K.B., Stoesser N., Matthews P.C., Diamond I., Studley R., Rourke E., Cook D., Bell J.I., Newton J.N., et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 2022;28:1072&#x2013;1082. doi: 10.1038/s41591-022-01721-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01721-6</ArticleId><ArticleId IdType="pmc">PMC9117148</ArticleId><ArticleId IdType="pubmed">35165453</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ltgen K., Nielsen S.C., Silva O., Younes S.F., Zaslavsky M., Costales C., Yang F., Wirz O.F., Solis D., Hoh R.A., et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025&#x2013;1040.e14. doi: 10.1016/j.cell.2022.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., Iyer N.S., Munter S.E., Nixon C.C., Donatelli J., Thanh C., Takahashi S., Hakim J., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36:109518. doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundura L., Cezar R., Andr&#xe9; S., Campos-Mora M., Lozano C., Vincent T., Muller L., Lefrant J.-Y., Roger C., Claret P.-G., et al. Low perforin expression in CD8+ T lymphocytes during the acute phase of severe SARS-CoV-2 infection predicts long COVID. Front. Immunol. 2022;13:1029006. doi: 10.3389/fimmu.2022.1029006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1029006</ArticleId><ArticleId IdType="pmc">PMC9630742</ArticleId><ArticleId IdType="pubmed">36341327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>